Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BGY-1601-VT

Phase 2Small molecule

NNEXBIOME THERAPEUTICS

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Clinical

Trials by Indication[1]

Infection1 trial

Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection

Not yet recruiting·NNEXBIOME THERAPEUTICS·Phase 1/2·NCT06450990·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BGY-1601-VT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGY-1601-VT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGY-1601-VT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NEXBIOME THERAPEUTICS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNEXBIOME THERAPEUTICS

Related News